1. Introduction {#sec1}
===============

Kaposi\'s Sarcoma is a cancer that occurs mostly in humans with suppressed immune systems \[[@B3]\]. The development of this cancer depends upon prior infection to the human herpesvirus-8 (HHV-8) \[[@B11]\], a virus which is usually transmitted either sexually or via saliva \[[@B10]\]. For HIV-related Kaposi\'s Sarcoma development, immunosuppression is a necessary causal factor \[[@B11]\]. Because HIV is an immunosuppressive virus, it promotes the development of Kaposi\'s Sarcoma in individuals dually infected with both viruses (HIV and HHV-8) and this combination has proved to be fatal and has made Kaposi\'s Sarcoma the fourth largest killer of people living with HIV/AIDS in sub-Sahara Africa \[[@B23]\].

In competent immune systems, acquisition of HHV-8 does not guarantee the development of KS; in fact, most individuals with a strong immune response could remain latently infected with HHV-8 throughout their lifetime \[[@B11]\]. The HIV-1 growth factors stimulate the immune cells including the healthy and infected B-cells to proliferate. The activation of latently infected B-cells to proliferate only leads to production of more HHV-8 that, according to the theory proposed by Foreman et al. \[[@B11]\], may be responsible for infection of progenitor cells of endothelial origin, which once infected with HHV-8 develop into Kaposi\'s Sarcoma cells \[[@B11]\].

Recent research findings \[[@B13]\] show that highly active antiretroviral therapy (HAART) for HIV significantly decreases (and, in some instances, completely forces the cancer into remission) KS activity in a patient, but such treatment is only effective against persons who have seroconverted. Lungu et al. studied the within-host dynamics of HIV and KS and came to the conclusion that HIV infection accentuates the potential for infected individuals to develop KS conditions and that administration of HAART on KS individuals who have seroconverted results in the reversal of KS conditions. However, the same result could not be demonstrated if HAART was administered to HIV negative individuals.

From what has been described above, we formulate a mathematical model which includes the following classes: a susceptible class, *S*, two infected classes of individuals infected with HIV-1 only, *I*, individuals coinfected with HHV-8 and HIV-1, *I* ~*k*~, two classes of asymptomatic infectives with HIV only, *P*, asymptomatic coinfected, *P* ~*k*~, a class of treated individuals, *T*, and two AIDS classes, namely, individuals with full-blown AIDS only, *A*, and individuals coinfected with full-blown AIDS and Kaposi\'s Sarcoma.

The structure of the paper is as follows. In [Section 2](#sec2){ref-type="sec"} we formulate the model that describes the coinfection transmission dynamics. Existence of solutions is proved in [Section 3](#sec3){ref-type="sec"}, but our main interest is to simulate and study the dynamic behavior of the steady state solution. In particular, we want to quantify the proportion of HAART-treated individuals who never develop KS at various treatment rates *ϕ* ~1~ and *ϕ* ~2~.

AIDS is the progressive stage at which an HIV-infected individual loses competency of his immune system and becomes prone to opportunistic infections. For this reason, HIV coinfection models have found a lot of space in HIV epidemiology studies. HIV and tuberculosis coinfection have been studied by Cohen et al. \[[@B9]\], Roeger et al. \[[@B21]\], and Ramkissoon et al. \[[@B20]\] while Barley et al. \[[@B2]\], Chiyaka et al. \[[@B8]\], and Mukandavire et al. \[[@B18]\] studied HIV-malaria coinfection dynamics with each study giving results pertinent to the coinfection under investigation. The study of HIV-KS coinfection dynamics is still in infancy and, to the best of our knowledge, no mathematical modeling study has been carried out to assess the coinfection dynamics of HIV and KS at the population level in sub-Sahara Africa. Because our model incorporates HAART administration to all infective classes, it can provide insights into treatment strategies and, in particular, decide whether the current policy based on a CD4 count threshold to access treatment should be continued as a strategy.

2. Model Formulation {#sec2}
====================

We begin with a human population of susceptibles which is free of both KS and HIV denoted by *S*. This population is replenished at constant rate Λ through sexual maturity or immigration. Upon effective contact with individuals infected with the HIV virus, the new infectives progress into the infected class *I* at rate *λ* ~*h*~, where *λ* ~*h*~ denotes the force of infection.

For simplicity of the model, we assume that all individuals in the class *S* are latently infected with the HHV-8 virus which causes the KS infection. Therefore, in our model every class, except for the susceptible class, is assumed to be at risk of developing KS. HIV infection is known to promote or enhance the development of KS condition \[[@B12], [@B25]\], and so we assume that individuals in the class *I* can develop mild KS at rate *ϵ* ~1~ and move into the class of coinfected individuals KS denoted by *I* ~*k*~.

HIV-only and coinfected individuals are assumed to progress to the asymptomatic pre-AIDS classes (*P* and *P* ~*k*~) at the same constant rate *ψ* ~1~. Furthermore, persons in the pre-AIDS class are deemed to be sexually interacting and that individuals with mild KS in the *I* ~*k*~ class can develop acute KS, which manifests in the form of visible lesions \[[@B25]\] and severe debilitation. Due to the nature of these symptoms, we assume that individuals who develop acute KS will no longer be sexually interacting. Those individuals in the *I* ~*k*~ class, who develop acute KS, die at a disease induced rate *τ* ~1~.

We assume that all infected individuals in the classes *I* and *I* ~*k*~ are tested and if they are tested positive for HIV-1 they receive treatment at rate *ϕ* ~1~ and move into the class of treated individuals, *T*. Individuals in the pre-AIDS classes *P* and *P* ~*k*~ have higher viral loads and therefore possess less competent immune systems. These individuals will then present for medical attention at a higher rate *ϕ* ~2~ \> *ϕ* ~1~. HAART is known to reverse KS conditions for people with HIV \[[@B25]\], and so in the model we assume that the therapy is perfect in reversing mild KS conditions. Upon accessing HAART, individuals in the infective class *I* ~*k*~ and pre-AIDS class *P* ~*k*~ achieve full KS recovery and progress to the treated class *T*. Additionally, individuals in the pre-AIDS class *P* ~*k*~ progress to acute KS at rate *τ* ~2~ \> *τ* ~1~. Individuals in the pre-AIDS class *P* are at risk of developing KS at a constant rate *ϵ* ~2~. Individuals in the pre-AIDS classes *P* and *P* ~*k*~ develop clinical symptoms and progress to full-blown AIDS *A* and *A* ~*k*~, respectively, at rate *θ* ~1~. Progression to full-blown AIDS by persons in the class *T* represents treatment failure, and they progress to the class *A* at the same rate *θ* ~2~. Full-blown AIDS individuals *A* can also develop KS at rate *ϵ* ~3~ \> *ϵ* ~2~ \> *ϵ* ~1~ due to weakened immune systems. Persons in the full-blown AIDS classes have additional AIDS-induced mortality *δ* ~1~. Progression rate to acute KS for persons with full-blown AIDS is *τ* ~3~, which we assume to be greater than *τ* ~2~ and *τ* ~1~. Individuals in both AIDS classes are also subject to a natural mortality rate of *μ*.

The force of infection *λ* ~*h*~ depends on the probability of transmission per contact *β*, the proportion of infected individuals in each category (*I* and *I* ~*k*~), the proportion of infected individuals in receipt of HAART (*T*), and the pre-AIDS classes (*P* and *P* ~*k*~). Individuals in receipt of HAART have reduced viral load \[[@B24]\] and are therefore assumed to be less infectious relative to infectives not in receipt of HAART. This reduced infectiousness is modeled by *γ* ~1~ \< 1. Coinfected infectives and pre-AIDS individuals (*I* ~*k*~ and *P* ~*k*~) have weaker immune systems and are therefore likely to carry higher viral loads than their counterparts in the (*I* and *P*) classes. This added infectiousness is modeled by *γ* ~2~ \> 1 and *γ* ~4~ \> 1. Pre-AIDS infectives *A* are more infectious because of increased viral load, and this increased infectiousness is modeled by *γ* ~3~ where *γ* ~1~ \< 1 \< *γ* ~2~ \< *γ* ~3~ \< *γ* ~4~. Persons with full-blown AIDS exhibit symptoms related to HIV and therefore are assumed to be noninteracting. The total sexually active variable population at time *t* is given by *N*(*t*) = *S*(*t*) + *I*(*t*) + *I* ~*k*~(*t*) + *P*(*t*) + *P* ~*k*~(*t*) + *T*(*t*). Assuming homogeneous mixing, the time dependent force of infection for HIV is given by $$\begin{matrix}
{\lambda_{h} = \beta\left\lbrack \frac{\gamma_{1}T + I + \gamma_{2}I_{k} + \gamma_{3}P + \gamma_{4}P_{k}}{S + T + I + I_{k} + P\left( t \right) + P_{k}} \right\rbrack.} \\
\end{matrix}$$

The model flow diagram depicting this biological system is illustrated in [Figure 1](#fig1){ref-type="fig"}.

The above assumptions and formulations lead us to this nonlinear system of differential equations: $$\begin{matrix}
{S^{\prime}\left( t \right) = \Lambda - \left( \lambda_{h} + \mu \right)S\left( t \right),} \\
{I^{\prime}\left( t \right) = \lambda_{h}S\left( t \right) - \left( \epsilon_{1} + \mu + \psi_{1} + \phi_{1} \right)I\left( t \right),} \\
{I_{k}^{\prime}\left( t \right) = \epsilon_{1}I\left( t \right) - \left( \mu + \psi_{1} + \phi_{1} + \tau_{1} \right)I_{k}\left( t \right),} \\
{P^{\prime}\left( t \right) = \psi_{1}I\left( t \right) - \left( \phi_{2} + \epsilon_{2} + \theta_{1} + \mu \right)P\left( t \right),} \\
{P_{k}^{\prime}\left( t \right) = \epsilon_{2}P\left( t \right) + \psi_{1}I_{k} - \left( \phi_{2} + \theta_{1} + \mu + \tau_{2} \right)P_{k}\left( t \right),} \\
{T^{\prime}\left( t \right) = \phi_{1}\left( I\left( t \right) + I_{k}\left( t \right) \right) + \phi_{2}\left( P\left( t \right) + P_{k}\left( t \right) \right) - \left( \theta_{2} + \mu \right)T\left( t \right),} \\
{A^{\prime}\left( t \right) = \theta_{1}P\left( t \right) + \theta_{2}T\left( t \right) - \left( \epsilon_{3} + \delta_{1} + \mu \right)A\left( t \right),} \\
{A_{k}^{\prime}\left( t \right) = \theta_{1}P_{k}\left( t \right) + \epsilon_{3}A\left( t \right) - \left( \delta_{1} + \delta_{2} + \mu \right)A_{k}\left( t \right).} \\
\end{matrix}$$

All parameters for the model system ([2](#EEq2){ref-type="disp-formula"}) are assumed to be nonnegative for all time *t* \> 0.

3. Basic Properties {#sec3}
===================

3.1. Positivity and Boundedness of Solutions {#sec3.1}
--------------------------------------------

We denote by *R* ~+~ ^8^ the set of points *x* ~*t*~ = (*x* ~1~, *x* ~2~, *x* ~3~, *x* ~4~, *x* ~5~, *x* ~6~, *x* ~7~, *x* ~8~) in *R* ^8^ with positive coordinates and consider the system ([2](#EEq2){ref-type="disp-formula"}) with initial values $$\begin{matrix}
{x^{0} = \left( x_{1}^{0},x_{2}^{0},x_{3}^{0},x_{4}^{0},x_{5}^{0},x_{6}^{0},x_{7}^{0},x_{8}^{0} \right).} \\
\end{matrix}$$

In this section, we prove the following lemma.

LemmaThe system ([2](#EEq2){ref-type="disp-formula"}) can be written as a system of differential inequalities $$\begin{matrix}
{\frac{dx_{i}}{dt} \geq A_{i}x_{i} + \sum\limits_{j}^{n}B_{ij}x_{j} + \epsilon\quad\left( {i = 1,\ldots,n} \right),} \\
\end{matrix}$$ where $$\begin{matrix}
{B_{ij} \geq 0,\quad\epsilon \geq 0.} \\
\end{matrix}$$ If *x* ~*i*~(0) ≥ *ϵ* then *x* ~*i*~(*t*) ≥ 0 for all *t* \> 0 and 1 ≤ *i* ≤ *n*.

Without loss of generality we may assume that *ϵ* \> 0, since the case *ϵ* = 0 follows by approximating the system with a sequence *ϵ* = *ϵ* ~*k*~ ↓ 0.

ProofSuppose that the assertion *x* ~*i*~(0) ≥ *ϵ* \> 0, for 1 ≤ *i* ≤ *n*, is not true. Then there exists the smallest number *t* ~0~ \> 0, such that $$\begin{matrix}
{x_{i}\left( t \right) > 0\quad\text{for}\,\, 1 \leq i \leq n,\,\, 0 \leq t \leq t_{0},} \\
{x_{i}\left( t_{0} \right) = 0\quad\text{for}\,\,\text{at}\,\,\text{least}\,\,\text{one}\,\, i,\,\,\text{say}\,\, i = i_{0}.} \\
\end{matrix}$$Then *x* ~*i*~0~~ is a decreasing function at *t* = *t* ~0~, so that $$\begin{matrix}
{\frac{dx_{i_{0}}}{dt}\left( t_{0} \right) \leq 0.} \\
\end{matrix}$$From the differential inequality ([4](#EEq4){ref-type="disp-formula"}) for *x* ~*i*~0~~(*t*) we get $$\begin{matrix}
{\frac{dx_{i_{0}}}{dt}\left( t_{0} \right) \geq \sum\limits_{j}^{n}B_{ij}x_{j} + \epsilon \geq \epsilon > 0} \\
\end{matrix}$$ which is a contradiction.For the state variables in our model, we always take $$\begin{matrix}
{S\left( 0 \right) \geq 0,\quad\quad I\left( 0 \right) \geq 0,\quad\quad I_{k}\left( 0 \right) \geq 0,\quad\quad P\left( 0 \right) \geq 0,} \\
{P_{k}\left( 0 \right) \geq 0,\quad\quad T\left( 0 \right) \geq 0,\quad\quad A\left( 0 \right) \geq 0,\quad\quad A_{k}\left( 0 \right) \geq 0.} \\
\end{matrix}$$From [Lemma 1](#lem1){ref-type="statement"} we conclude that $$\begin{matrix}
{S\left( t \right) \geq 0,\quad\quad I\left( t \right) \geq 0,\quad\quad I_{k}\left( t \right) \geq 0,\quad\quad P\left( t \right) \geq 0,} \\
{P_{k}\left( t \right) \geq 0,\quad\quad T\left( t \right) \geq 0,\quad\quad A\left( t \right) \geq 0,\quad\quad A_{k}\left( t \right) \geq 0.} \\
\end{matrix}$$Thus, in the region *R* ~+~ ^8^ the model is epidemiologically and mathematically well posed and we can use it to study the dynamics of HIV-KS coinfection.

### 3.1.1. Equilibrium States, Reproductive Number, and Stability Analysis {#sec3.1.1}

The model ([2](#EEq2){ref-type="disp-formula"}) possesses a disease-free equilibrium, *ξ* ~0~, given by $$\begin{matrix}
{\xi_{0} = \left\{ S,I,I_{k},P,P_{k},T,A,A_{k} \right\} = \left\{ {\left( \frac{\Lambda}{\mu} \right),0,0,0,0,0,0,0} \right\},} \\
\end{matrix}$$ and at least one endemic equilibrium state whose existence is discussed in [Section 3.3](#sec3.3){ref-type="sec"}. Following Van Den Driessche and Watmough \[[@B26]\], the KS-induced reproductive number of system ([2](#EEq2){ref-type="disp-formula"}), *ℛ* ~*k*~, is given by the spectral radius of the matrix *FV* ^−1^ where the matrices *F* and *V* are given by $$\begin{matrix}
{F = \begin{pmatrix}
\beta & {\gamma_{3}\beta} & {\gamma_{2}\beta} & {\gamma_{4}\beta} & {\gamma_{1}\beta} \\
0 & 0 & 0 & 0 & 0 \\
0 & 0 & 0 & 0 & 0 \\
0 & 0 & 0 & 0 & 0 \\
0 & 0 & 0 & 0 & 0 \\
\end{pmatrix},} \\
{V = \begin{pmatrix}
{- K_{1}} & 0 & 0 & 0 & 0 \\
\psi_{1} & {- K_{2}} & 0 & 0 & 0 \\
\epsilon_{1} & 0 & {- K_{3}} & 0 & 0 \\
0 & \epsilon_{2} & \psi_{1} & {- K_{4}} & 0 \\
\phi_{1} & \phi_{2} & \phi_{1} & \phi_{2} & {- K_{5}} \\
\end{pmatrix},} \\
\end{matrix}$$ where $$\begin{matrix}
{K_{1} = \left( \mu + \epsilon_{1} + \phi_{1} + \psi_{1} \right),} \\
{K_{2} = \left( \mu + \epsilon_{2} + \theta_{1} + \phi_{2} \right),} \\
{K_{3} = \left( \mu + \tau_{1} + \phi_{1} + \psi_{1} \right),} \\
{K_{4} = \left( \mu + \theta_{1} + \tau_{2} + \phi_{2} \right),} \\
{K_{5} = \left( {\mu + \theta_{2}} \right).} \\
\end{matrix}$$

From ([12](#EEq6){ref-type="disp-formula"}) we have calculated the reproduction number $$\begin{matrix}
{\mathcal{R}_{k} = \mathcal{R}_{I} + \mathcal{R}_{I_{k}} + \mathcal{R}_{P} + \mathcal{R}_{P_{k}} + \mathcal{R}_{T},} \\
\end{matrix}$$ where $$\begin{matrix}
{\mathcal{R}_{I} = \frac{\beta}{\left( \mu + \epsilon_{1} + \phi_{1} + \psi_{1} \right)},} \\
{\mathcal{R}_{I_{k}} = \frac{\beta\gamma_{2}\epsilon_{1}}{\left( \mu + \epsilon_{1} + \phi_{1} + \psi_{1} \right)\left( \mu + \tau_{1} + \phi_{1} + \psi_{1} \right)},} \\
{\mathcal{R}_{P} = \frac{\beta\gamma_{3}\psi_{1}}{\left( {\mu + \epsilon_{2} + \theta_{1} + \phi_{2}} \right)\left( {\mu + \epsilon_{1} + \phi_{1} + \psi_{1}} \right)},} \\
{\mathcal{R}_{P_{k}} = \,\beta\gamma_{4}\psi_{1}\,} \\
{\times \left( {\epsilon_{1}\left( {\mu + \epsilon_{2} + \theta_{1} + \phi_{2}} \right) + \epsilon_{2}\left( {\mu + \tau_{1} + \phi_{1} + \psi_{1}} \right)} \right)} \\
{\times \left( {\left( {\mu + \epsilon_{2} + \theta_{1} + \phi_{2}} \right)\left( {\mu + \theta_{1} + \tau_{2} + \phi_{2}} \right)} \right.} \\
{\quad\quad\quad\left. {\times \left( {\mu + \epsilon_{1} + \phi_{1} + \psi_{1}} \right)\left( {\mu + \tau_{1} + \phi_{1} + \psi_{1}} \right)} \right)^{- 1},} \\
{\mathcal{R}_{T} = \mathcal{R}_{T_{I}} + \mathcal{R}_{T_{2}} + \mathcal{R}_{T_{3}} + \mathcal{R}_{T_{4}} + \mathcal{R}_{T_{5}},} \\
{\mathcal{R}_{T_{1}} = \frac{\beta\gamma_{1}\phi_{1}}{\left( {\mu + \theta_{2}} \right)\left( {\mu + \epsilon_{1} + \phi_{1} + \psi_{1}} \right)},} \\
{\mathcal{R}_{T_{2}} = \frac{\beta\gamma_{1}\phi_{2}\psi_{1}}{\left( {\mu + \theta_{2}} \right)\left( {\mu + \epsilon_{2} + \theta_{1} + \phi_{2}} \right)\left( {\mu + \epsilon_{1} + \phi_{1} + \psi_{1}} \right)},} \\
{\mathcal{R}_{T_{3}} = \frac{\beta\gamma_{1}\epsilon_{1}\phi_{1}}{\left( {\mu + \theta_{2}} \right)\left( {\mu + \epsilon_{1} + \phi_{1} + \psi_{1}} \right)\left( {\mu + \tau_{1} + \phi_{1} + \psi_{1}} \right)},} \\
{\mathcal{R}_{T_{4}} = \beta\gamma_{1}\epsilon_{1}\phi_{2}\psi_{1}} \\
{\times \left( {\left( {\mu + \theta_{2}} \right)\left( {\mu + \theta_{1} + \tau_{2} + \phi_{2}} \right)} \right.} \\
{\quad\quad\quad \times \left. {\left( {\mu + \epsilon_{1} + \phi_{1} + \psi_{1}} \right)\left( {\mu + \tau_{1} + \phi_{1} + \psi_{1}} \right)} \right)^{- 1},} \\
{\mathcal{R}_{T_{5}} = \beta\gamma_{1}\epsilon_{2}\phi_{2}\psi_{1}} \\
{\times \left( {\left( {\mu + \theta_{2}} \right)\left( {\mu + \epsilon_{2} + \theta_{1} + \phi_{2}} \right)} \right.} \\
{\quad\quad\quad \times \left. {\left( {\mu + \theta_{1} + \tau_{2} + \phi_{2}} \right)\left( {\mu + \epsilon_{1} + \phi_{1} + \psi_{1}} \right)} \right)^{- 1}.} \\
\end{matrix}$$

This number *ℛ* ~*k*~ is a threshold such that if *ℛ* ~*k*~ \< 1 the disease clears from the population. If *ℛ* ~*k*~ \> 1 the steady state *ξ* ~0~ becomes unstable and the disease establishes itself into the population. This number is comprehensively analyzed further in [Section 3.4](#sec3.4){ref-type="sec"} to reveal the impact of treatment.

3.2. Global Stability of the Disease-Free Equilibrium {#sec3.2}
-----------------------------------------------------

If *ℛ* ~*k*~ \< 1 then fixed point *ℰ* ~0~ is locally asymptotically stable. We now determine conditions which guarantee global asymptotic stability of the disease-free state \[[@B7]\]. Rewrite model system ([2](#EEq2){ref-type="disp-formula"}) as $$\begin{matrix}
{\frac{dX}{dt} = F\left( \mathbf{x},Z \right),} \\
{\frac{dZ}{dt} = G\left( {X,Z} \right),\quad\quad G\left( {\mathbf{x},0} \right) = 0,} \\
\end{matrix}$$ where *X* ∈ ℝ^*m*^ denotes the number of uninfected individuals and *Z* ∈ ℝ^*n*^ denotes the number of infected individuals including those latently infected and those who are infectious. The disease-free equilibrium state can now be written as $$\begin{matrix}
{U_{0} = \left( {X^{\ast},0} \right),} \\
\end{matrix}$$ where *X*\* = ((Λ/*μ*), 0,0, 0,0, 0,0, 0,0). To guarantee global stability, the following conditions must be satisfied: for *dX*/*dt* = *F*(*X*, 0), *X*\* is globally asymptotically stable;$G(X,Z) = \text{A}Z - \hat{G}(X,Z),\hat{G}(X,Z) \geq 0$ for (*X*, *Z*) ∈ *Ω*;*A* = *D* ~*Z*~ *G*(*X*\*, 0) is an *M*-matrix (the off diagonal elements of *A* are nonnegative) and *Ω* is the region where the model makes biological sense.

Lemma 2The fixed point *U* ~0~ = (*X*\*, 0) is a globally asymptotically stable point of ([2](#EEq2){ref-type="disp-formula"}) provided that *ℛ* ~*k*~ \< 1 and conditions stated above are satisfied.

ProofConsider $$\begin{matrix}
{F\left( X,0 \right) = \begin{pmatrix}
{\Lambda - \mu S_{f}} \\
0 \\
0 \\
0 \\
0 \\
\end{pmatrix},} \\
{G\left( X,Z \right) = AZ - \hat{G}\left( X,Z \right),} \\
{A = \begin{pmatrix}
{\beta - K_{1}} & {\gamma_{3}\beta} & {\gamma 2\beta} & {\gamma_{4}\beta} & {\gamma_{1}\beta} \\
\psi_{1} & {- K_{2}} & 0 & 0 & 0 \\
\epsilon_{1} & 0 & {- K_{3}} & 0 & 0 \\
0 & \epsilon_{2} & \psi_{1} & {- K_{4}} & 0 \\
\phi_{1} & \phi_{2} & \phi_{1} & \phi_{2} & {- K_{5}} \\
\end{pmatrix}.} \\
\end{matrix}$$Then $$\begin{matrix}
{\hat{G}\left( {X,Z} \right) = \beta\left( {\gamma_{1}T + I_{m} + \gamma_{2}I_{k} + \gamma_{3}P + \gamma_{4}P_{k}} \right)} \\
{\times \begin{pmatrix}
\left( {1 - \frac{S}{S + I + I_{k} + P + P_{k}}} \right) \\
0 \\
0 \\
0 \\
0 \\
\end{pmatrix}.} \\
\end{matrix}$$Since 0 ≤ *S* ≤ *S* + *I* + *I* ~*k*~ + *P* + *P* ~*k*~, it is clear that $\hat{G}(X,Z) \geq 0$ and *A* is an *M*-matrix whenever its spectral radius is less than unity. Then, by [Lemma 2](#lem2){ref-type="statement"}, *ξ* ~0~ is a globally asymptotically stable equilibrium of ([2](#EEq2){ref-type="disp-formula"}).

The biological interpretation of [Lemma 2](#lem2){ref-type="statement"} is that this population is observing the one partner policy or abstinence from unprotected sex resulting in HIV being eliminated from the population regardless of the size of the initial subpopulations \[[@B22]\].

3.3. Existence of Endemic Equilibria and Bifurcation Analysis {#sec3.3}
-------------------------------------------------------------

In this section following the approach in \[[@B14]\], we establish conditions for the existence of endemic equilibria and investigate their stability. Denote the arbitrary endemic equilibrium of model ([2](#EEq2){ref-type="disp-formula"}) by *ℰ*\* where $$\begin{matrix}
{\mathcal{E}^{\ast} = \left( S^{\ast},I^{\ast},I_{k}^{\ast},T^{\ast}P^{\ast},P^{\ast},A^{\ast},A_{k}^{\ast} \right).} \\
\end{matrix}$$

Let $$\begin{matrix}
{\lambda_{h}^{\ast} = \beta\left\lbrack \frac{\gamma_{1}T^{\ast} + I^{\ast} + \gamma_{2}I_{k}^{\ast} + \gamma_{3}P^{\ast} + \gamma_{4}P_{k}^{\ast}}{S^{\ast} + T^{\ast} + I^{\ast} + I_{k}^{\ast} + P^{\ast}\left( t \right) + P_{k}^{\ast}} \right\rbrack,} \\
\end{matrix}$$ be the force of infection. By setting the right hand side of model ([2](#EEq2){ref-type="disp-formula"}) to zero, we obtain, in terms of the force of infection, $$\begin{matrix}
{S^{\ast} = \frac{\Lambda}{\lambda_{h}^{\ast} + \mu},\quad\quad I^{\ast} = \frac{\lambda_{h}^{\ast}}{K_{1}},\quad\quad I_{k}^{\ast} = \frac{\epsilon_{1}I^{\ast}}{K_{2}},} \\
{T^{\ast} = \frac{\psi_{1}I^{\ast}}{K_{3}},\quad\quad P^{\ast} = \frac{\left( {\psi_{1}I_{k}^{\ast} + \epsilon_{2}P^{\ast}} \right)}{K_{4}},} \\
{A^{\ast} = \frac{\left( {\theta_{1}I^{\ast} + \theta_{2}T^{\ast}} \right)}{\left( {\epsilon_{2} + \mu + \delta_{1}} \right)},\quad\quad A_{k} = \frac{\left( {\theta_{1}I_{k} + \epsilon_{3}A_{k}} \right)}{\left( {\mu + \delta_{1} + \delta_{2}} \right)}.} \\
\end{matrix}$$

Substituting the values of *S*\*, *I*\*, *I* ~*k*~\*, *T*\**P*\*, *P*\*, *A*\*, and *A* ~*k*~\* into ([21](#EEq14){ref-type="disp-formula"}) we obtain the polynomial $$\begin{matrix}
{a_{0}\lambda_{h}^{2} + K_{1}\lambda_{h} = 0,} \\
\end{matrix}$$ where $$\begin{matrix}
{a_{0} = K_{2}K_{4}\left( {K_{3} + \epsilon_{1}} \right)\left( {\mu + \theta_{2} + \phi_{1}} \right)} \\
{+ \left( {K_{2}\epsilon_{1} + K_{3}\left( {K_{4} + \epsilon_{2}} \right)} \right)\left( {\mu + \theta_{2} + \phi_{2}} \right)\psi_{1},} \\
{a_{1} = - \beta\gamma_{1}\left( {K_{3} + \epsilon_{1} + \left( {K_{2}\epsilon_{1} + K_{3}\left( {K_{4} + \epsilon_{2}} \right)} \right)\phi_{2}\psi_{1}} \right)} \\
{+ \left( {\mu + \theta_{2}} \right)\left( {- \beta K_{3}\left( {K_{4}\gamma_{3} + \gamma_{4}\epsilon_{2}} \right)\psi_{1} - K_{2}\left( {\beta - K_{1}} \right)K_{3}K_{4}} \right.} \\
{\left. {\quad + \beta\epsilon_{1}\left( {K_{4}\gamma_{2} + \gamma_{4}\psi_{1}} \right)} \right).{\,\,}} \\
\end{matrix}$$ Equation ([23](#EEq15){ref-type="disp-formula"}) has two solutions given by $$\begin{matrix}
{\lambda_{h0} = 0,} \\
{\lambda_{h1} = K_{1}K_{2}K_{3}K_{4}\left( {K_{2}K_{4}\left( {\mathcal{R}_{K} - 1} \right)K_{6}K_{8} + \mathcal{R}_{K}\gamma_{1}K_{9}\phi_{1}} \right.} \\
{\left. {+ \left( {\mathcal{R}_{K} - 1} \right)K_{10}K_{8} + \mathcal{R}_{K}\gamma_{1}K_{7}\phi_{2}} \right)\psi_{1}} \\
{\times \left( \left( {K_{2}K_{4}K_{9}\left( {K_{8} + \phi_{1}} \right) + K_{7}\left( {K_{8} + \phi_{2}} \right)\psi_{1}} \right) \right.} \\
{\quad\quad\quad \times \left. \left( {K_{5}\psi_{1} + K_{2}\left( {K_{4}K_{6} + \gamma_{4}\epsilon_{1}\psi_{1}} \right)} \right) \right)^{- 1},} \\
\end{matrix}$$ where $$\begin{matrix}
{K_{5} = K_{3}\left( K_{4}\gamma_{3} + \gamma_{4}\epsilon_{2} \right),\quad K_{6} = \left( K_{3} + \gamma_{2}\epsilon_{1} \right),} \\
{K_{8} = \left( \mu + \theta_{2} \right),\quad K_{9} = \left( K_{3} + \epsilon_{1} \right),\quad K_{10} = \left( K_{2}\gamma_{4}\epsilon_{1} + K_{5} \right).} \\
\end{matrix}$$

From the solution *λ* ~*h*1~, the condition *ℛ* ~*K*~ \> 1 is necessary for existence of the nontrivial endemic equilibrium and we summarize this as follows.

Lemma 3The model ([2](#EEq2){ref-type="disp-formula"}) has a unique endemic equilibrium whenever *ℛ* ~*k*~ \> 1.

Having proved the existence of the endemic equilibrium point we now investigate its stability using the Centre Manifold Theory \[[@B5]\] as described by Castillo-Chavez and Song \[[@B6]\]. Consider the following general system of ordinary differential equations with a parameter *ϕ* $$\begin{matrix}
\left. \frac{dx}{dt} = f\left( {x,\phi} \right),\quad f:{\mathbb{R}}^{n} \times {\mathbb{R}}\rightarrow{\mathbb{R}},\,\, f \in C^{2}\left( {\mathbb{R}} \times {\mathbb{R}} \right). \right. \\
\end{matrix}$$

Without loss of generality, it is assumed that 0 is an equilibrium for system ([27](#EEq16){ref-type="disp-formula"}) for all values of the parameter *ϕ*, (i.e., *f*(*ϕ*, 0) ≡ 0 for all *ϕ*).

Assume the following.(A1):*A* = *D* ~*x*~ *f*(0,0) = ((∂*f* ~*i*~/∂*x* ~*j*~)(0,0)) is the linearise matrix of system ([27](#EEq16){ref-type="disp-formula"}) around the equilibrium 0 with *ϕ* evaluated at 0. Zero is a simple eigenvalue of *A* and all other eigenvalues of *A* have negative real parts.(A2):Matrix *A* has a nonnegative right eigenvector *w* and a left eigenvector *v* corresponding to the zero eigenvalue.

Let *f* ~*k*~ be the *k*th component of *f* and $$\begin{matrix}
{a = \sum\limits_{k,i,j = 1}^{n}v_{k}w_{i}w_{j}\frac{\partial^{2}f_{k}}{\partial x_{i}\partial x_{j}}\left( 0,0 \right),} \\
{b = \sum\limits_{k,i = 1}^{n}v_{k}w_{i}\frac{\partial^{2}f_{k}}{\partial x_{i}\partial\phi}\left( 0,0 \right).} \\
\end{matrix}$$

The local dynamics of system ([27](#EEq16){ref-type="disp-formula"}) around 0 are totally determined by *a* and *b*. *a* \> 0, *b* \> 0. When *ϕ* \< 0 with \|*ϕ*\| ≪ 1, 0 is locally asymptotically stable and there exists a positive unstable equilibrium; when 0 \< *ϕ* ≪ 1, 0 is unstable and there exists a negative and locally asymptotically stable equilibrium.*a* \< 0, *b* \< 0. When *ϕ* \< 0 with \|*ϕ*\| ≪ 1, 0 is unstable; when 0 \< *ϕ* ≪ 1, 0 is locally asymptotically stable, and there exists a positive unstable equilibrium.*a* \> 0, *b* \< 0. When *ϕ* \< 0 with \|*ϕ*\| ≪ 1, 0 is unstable, and there exists a locally asymptotically stable negative equilibrium; when 0 \< *ϕ* ≪ 1, 0 is stable, and a positive unstable equilibrium appears.*a* \< 0, *b* \> 0. When *ϕ* changes from negative to positive, 0 changes its stability from stable to unstable. Correspondingly, a negative unstable equilibrium becomes positive and locally asymptotically stable. Particularly, if *a* \> 0 and *b* \> 0, then, a backward bifurcation occurs at *ϕ* = 0.

We make the following change of variables: *S* = *x* ~1~, *I* = *x* ~2~, *I* ~*k*~ = *x* ~3~, *P* = *x* ~4~, *P* ~*k*~ = *x* ~5~, *T* = *x* ~6~, *A* = *x* ~7~, and *A* ~*k*~ = *x* ~8~ so that *N* = ∑~*n*=1~ ^8^ *x* ~*n*~. We now use the vector notation *X* = (*x* ~1~, *x* ~2~, *x* ~3~, *x* ~4~, *x* ~5~, *x* ~6~, *x* ~7~, *x* ~8~)^*T*^. Then, model system ([2](#EEq2){ref-type="disp-formula"}) can be written in the form *dX*/*dt* = *F* = (*f* ~1~, *f* ~2~, *f* ~3~, *f* ~4~, *f* ~5~, *f* ~6~, *f* ~7~, *f* ~8~)^*T*^, such that $$\begin{matrix}
{x_{1}^{\prime}\left( t \right) = f_{1} = \Lambda - \left( \lambda_{h} + \mu \right)x_{1}\left( t \right),} \\
{x_{2}^{\prime}\left( t \right) = f_{2} = \lambda_{h}x_{1}\left( t \right) - \left( \epsilon_{1} + \mu + \psi_{1} + \phi_{1} \right)x_{2}\left( t \right),} \\
{x_{3}^{\prime}\left( t \right) = f_{3} = \epsilon_{1}x_{2}\left( t \right) - \left( \mu + \psi_{1} + \phi_{1} + \tau_{1} \right)x_{3}\left( t \right),} \\
{x_{4}^{\prime}\left( t \right) = f_{4} = \psi_{1}x_{2}\left( t \right) - \left( \phi_{2} + \epsilon_{2} + \theta_{1} + \mu \right)x_{4}\left( t \right),} \\
{x_{5}^{\prime}\left( t \right) = f_{5} = \epsilon_{2}x_{4}\left( t \right) + \psi_{1}x_{3} - \left( \phi_{2} + \theta_{1} + \mu + \tau_{2} \right)x_{5}\left( t \right),} \\
{x_{6}^{\prime}\left( t \right) = f_{6} = \phi_{1}\left( {x_{2}\left( t \right) + x_{3}\left( t \right)} \right) + \phi_{2}\left( {x_{4}\left( t \right) + x_{5}\left( t \right)} \right)} \\
{- \left( {\theta_{2} + \mu} \right)x_{6}\left( t \right),} \\
{x_{7}^{\prime}\left( t \right) = f_{7} = \theta_{1}x_{4}\left( t \right) + \theta_{2}x_{6}\left( t \right) - \left( \epsilon_{3} + \delta_{1} + \mu \right)x_{7}\left( t \right),} \\
{x_{8}^{\prime}\left( t \right) = f_{8} = \theta_{1}x_{5}\left( t \right) + \epsilon_{3}x_{7}\left( t \right) - \left( \delta_{1} + \delta_{2} + \mu \right)x_{8}\left( t \right),} \\
\end{matrix}$$ where $$\begin{matrix}
{\lambda_{h} = \frac{\gamma_{1}x_{6} + x_{2} + \gamma_{2}x_{3} + \gamma_{3}x_{4} + \gamma_{4}x_{5}}{x_{1} + x_{2} + x_{3} + x_{4} + x_{5} + x_{6}}.} \\
\end{matrix}$$

The Jacobian matrix of system ([29](#EEq18){ref-type="disp-formula"}) at the disease-free equilibrium is given by $$\begin{matrix}
{J\left( \xi_{0} \right) = \begin{pmatrix}
{\beta - K_{1}} & {\gamma_{3}\beta} & {\gamma 2\beta} & {\gamma_{4}\beta} & {\gamma_{1}\beta} \\
\psi_{1} & {- K_{2}} & 0 & 0 & 0 \\
\epsilon_{1} & 0 & {- K_{3}} & 0 & 0 \\
0 & \epsilon_{2} & \psi_{1} & {- K_{4}} & 0 \\
\phi_{1} & \phi_{2} & \phi_{1} & \phi_{2} & {- K_{5}} \\
\end{pmatrix},} \\
\end{matrix}$$ from which it can be shown that *ℛ* ~*k*~ is the same as in ([14](#EEq8){ref-type="disp-formula"}). If *β*\* is taken as a bifurcation point and if we consider the case *ℛ* ~1~ = 1 and solve for *β*\* = *β* gives $$\begin{matrix}
{\beta^{\ast} = \frac{1}{\mathcal{R}_{k}}.} \\
\end{matrix}$$

The linearised system of the transformed equations ([29](#EEq18){ref-type="disp-formula"}) at *β*\* has a simple zero eigenvalue. Hence, the Centre Manifold Theory \[[@B5]\] can be used to analyse the dynamics of system ([29](#EEq18){ref-type="disp-formula"}) near *β*\*. It can be shown that the Jacobian of ([29](#EEq18){ref-type="disp-formula"}) at *β*\* has a right eigenvector associated with the zero eigenvalue given by *u* = \[*u* ~1~, *u* ~2~, *u* ~3~, *u* ~4~, *u* ~5~, *u* ~6~, *u* ~7~, *u* ~8~\]^*T*^, where $$\begin{matrix}
{u_{2} = u_{2} > 0,\quad u_{3} = \frac{u_{2}\psi_{1}}{K_{2}} > 0,} \\
{u_{4} = \frac{u_{2}\epsilon_{1}}{K_{3}} > 0,\quad u_{6} = \frac{u_{2}\phi_{1} + u_{4}\phi_{1} + \left( u_{3} + u_{5} \right)\phi_{2}}{K_{5}} > 0,} \\
{u_{7} = \frac{u_{2}\theta_{1} + u_{6}\theta_{2}}{K_{6}} > 0,\quad u_{8} = \frac{u_{7}\epsilon_{3} + u_{4}\theta_{1}}{K_{7}} > 0,} \\
{u_{1} = - \frac{\beta\left( u_{2} + u_{6}\gamma_{1} + u_{4}\gamma_{2} + u_{3}\gamma_{3} + u_{5}\gamma_{4} \right)}{\mu} < 0.} \\
\end{matrix}$$

The left eigenvector of *J*(*ξ* ~0~) associated with the zero eigenvalue at *β* = *β*\* is given by *v* = \[*v* ~1~, *v* ~2~, *v* ~3~, *v* ~4~, *v* ~5~, *v* ~6~, *v* ~7~, *v* ~8~\] where $$\begin{matrix}
{v_{1} = v_{7} = v_{8} = 0,\quad v_{2} = v_{2} > 0,} \\
{v_{3} = \frac{\beta v_{2}\gamma_{3} + v_{5}\epsilon_{2} + v_{6}\phi_{2}}{K_{2}} > 0,\quad v_{4} = \frac{\beta v_{2}\gamma_{2} + v_{6}\phi_{1} + v_{5}\psi_{1}}{K_{3}},} \\
{v_{5} = \frac{\beta v_{2}\gamma_{4} + v_{6}\phi_{2}}{K_{4}},\quad v_{6} = \frac{\beta v_{2}\gamma_{1}}{K_{5}}.} \\
\end{matrix}$$

For the model system ([2](#EEq2){ref-type="disp-formula"}), the associated nonzero partial derivatives of *F* at the disease-free equilibrium are given by $$\begin{matrix}
{\frac{\partial f_{2}^{2}}{\partial x_{2}\partial x_{2}} = - \frac{2\beta\mu}{\Lambda},\quad\frac{\partial f_{2}^{2}}{\partial x_{2}\partial x_{3}} = \frac{\partial f_{2}^{2}}{\partial x_{2}\partial x_{3}} = - \frac{\beta\mu\left( {1 + \gamma_{2}} \right)}{\Lambda},} \\
{\frac{\partial f_{2}^{2}}{\partial x_{2}\partial x_{4}} = \frac{\partial f_{2}^{2}}{\partial x_{4}\partial x_{2}} = - \frac{\beta\mu\left( 1 + \gamma_{3} \right)}{\Lambda},} \\
{\frac{\partial f_{2}^{2}}{\partial x_{2}\partial x_{5}} = - \frac{\partial f_{2}^{2}}{\partial x_{5}\partial x_{2}} = \frac{\beta\mu\left( {1 + \gamma_{4}} \right)}{\Lambda},} \\
{\frac{\partial f_{2}^{2}}{\partial x_{2}\partial x_{6}} = \frac{\partial f_{2}^{2}}{\partial x_{6}\partial x_{2}} = - \frac{\beta\mu u_{6}\left( 1 + \gamma_{1} \right)}{\Lambda},} \\
{\frac{\partial f_{2}^{2}}{\partial x_{3}\partial x_{3}} = - \frac{2\beta\mu\gamma_{2}}{\Lambda},\quad\frac{\partial f_{2}^{2}}{\partial x_{3}\partial x_{4}} = \frac{\partial f_{2}^{2}}{\partial x_{4}\partial x_{3}} = - \frac{\beta\mu\left( \gamma_{2} + \gamma_{3} \right)}{\Lambda},} \\
{\frac{\partial f_{2}^{2}}{\partial x_{3}\partial x_{5}} = \frac{\partial f_{2}^{2}}{\partial x_{5}\partial x_{3}} = - \frac{\beta\mu\left( {\gamma_{2} + \gamma_{4}} \right)}{\Lambda},} \\
{\frac{\partial f_{2}^{2}}{\partial x_{3}\partial x_{6}} = \frac{\partial f_{2}^{2}}{\partial x_{6}\partial x_{3}} = \frac{\beta\mu\left( \gamma_{1} + \gamma_{2} \right)}{\Lambda},} \\
{\frac{\partial f_{2}^{2}}{\partial x_{4}\partial x_{4}} = - \frac{2\beta\mu\gamma_{3}}{\Lambda},\quad\frac{\partial f_{2}^{2}}{\partial x_{4}\partial x_{5}} = \frac{\partial f_{2}^{2}}{\partial x_{5}\partial x_{4}} = \frac{\beta\mu\left( {\gamma_{3} + \gamma_{4}} \right)}{\Lambda},} \\
{\frac{\partial f_{2}^{2}}{\partial x_{4}\partial x_{6}} = \frac{\partial f_{2}^{2}}{\partial x_{6}\partial x_{4}} = - \frac{\beta\mu\left( \gamma_{1} + \gamma_{3} \right)}{\Lambda},} \\
{\frac{\partial f_{2}^{2}}{\partial x_{5}\partial x_{5}} = \frac{2\beta\mu\gamma_{4}}{\Lambda},\quad\frac{\partial f_{2}^{2}}{\partial x_{5}\partial x_{6}} = \frac{\partial f_{2}^{2}}{\partial x_{6}\partial x_{5}} = \frac{\beta\mu\left( {\gamma_{1} + \gamma_{4}} \right)}{\Lambda},} \\
{\frac{\partial f_{2}^{2}}{\partial x_{6}\partial x_{6}} = \frac{2\beta\mu\gamma_{1}}{\Lambda}.} \\
\end{matrix}$$

From ([28](#EEq17){ref-type="disp-formula"}), it follows that $$\begin{matrix}
{a = - \frac{1}{\Lambda K_{2}^{2}K_{3}^{2}K_{4}^{2}K_{5}^{2}}} \\
{\times \left( {2\beta\mu u_{2}^{2}v_{2}\left( {K_{2}K_{4}\left( {K_{3} + \epsilon_{1}} \right)\left( {K_{5} + \phi_{1}} \right)} \right.} \right.} \\
\left. {+ \left( {K_{2}\epsilon_{1} + K_{3}\left( {K_{4} + \epsilon_{2}} \right)} \right)\left( {K_{5} + \phi_{2}} \right)\psi_{1}} \right) \\
{\times \left( {K_{3}\left( {K_{5}\left( {a_{4}\gamma_{2} + \gamma_{4}\epsilon_{2}} \right) + \gamma_{1}\left( {K_{4} + \epsilon_{2}} \right)\phi_{2}} \right)\psi_{1}} \right.} \\
{\quad\quad\quad\quad + K_{2}\left( {K_{4}\left( {K_{5}\left( {K_{3} + \gamma_{3}\epsilon_{1}} \right) + \gamma_{1}\left( {K_{3} + \epsilon_{1}} \right)\phi_{1}} \right)} \right.} \\
{\quad\quad\left. \left. \left. {\quad\quad\quad\quad\quad\quad + \epsilon_{1}\left( {K_{5}\gamma_{4} + \gamma_{1}\phi_{2}} \right)\psi_{1}} \right) \right) \right)} \\
{< 0.} \\
\end{matrix}$$

For the sign of *b*, it is associated with the nonvanishing partial derivatives of *F*, $$\begin{matrix}
{\frac{\partial^{2}f_{2}}{\partial_{x_{2}}\partial_{\beta_{m}}} = 1,\quad\quad\frac{\partial^{2}f_{2}}{\partial_{x_{3}}\partial_{\beta_{m}}} = \gamma_{2},\quad\quad\frac{\partial^{2}f_{2}}{\partial_{x_{4}}\partial_{\beta_{m}}} = \gamma_{3},} \\
{\frac{\partial^{2}f_{2}}{\partial_{x_{5}}\partial_{\beta_{m}}} = \gamma_{4},\quad\quad\frac{\partial^{2}f_{2}}{\partial_{x_{6}}\partial_{\beta_{m}}} = \gamma_{1}.} \\
\end{matrix}$$

From ([28](#EEq17){ref-type="disp-formula"}), it follows that $$\begin{matrix}
{b = v_{2}\,\left\lbrack {u_{2}\frac{\partial^{2}f_{2}}{\partial_{x_{2}}\partial_{\beta_{m}}} + u_{3}\frac{\partial^{2}f_{2}}{\partial_{x_{3}}\partial_{\beta_{m}}} + u_{4}\frac{\partial^{2}f_{2}}{\partial_{x_{4}}\partial_{\beta_{m}}}} \right.} \\
{\left. {\quad\quad + u_{5}\frac{\partial^{2}f_{2}}{\partial_{x_{5}}\partial_{\beta_{m}}} + u_{6}\frac{\partial^{2}f_{2}}{\partial_{x_{6}}\partial_{\beta_{m}}}} \right\rbrack > 0.} \\
\end{matrix}$$

By Theorem 11 in \[[@B6]\] we establish result in [Lemma 4](#lem4){ref-type="statement"}.

LemmaSince *a* \< 0, then model system ([2](#EEq2){ref-type="disp-formula"}) has a forward transcritical bifurcation and a unique locally stable endemic equilibrium (*ℰ*\*) guaranteed by [Lemma 3](#lem3){ref-type="statement"} exists for *ℛ* ~*k*~ \> 1 but sufficiently close to 1.

3.4. Analysis of the Reproductive Number *ℛ* ~*k*~ {#sec3.4}
--------------------------------------------------

To analyze the coinfection dynamics of KS and HIV, we investigate the KS-induced reproductive number in ([14](#EEq8){ref-type="disp-formula"}). In ([14](#EEq8){ref-type="disp-formula"}), we note that the partial reproductive numbers *ℛ* ~*I*~, *ℛ* ~*I*~*K*~~, *ℛ* ~*P*~, *ℛ* ~*P*~*K*~~, and *ℛ* ~*T*~ represent the contribution to the reproduction number *ℛ* ~*k*~ from the following classes of infectives HIV only (*I*), coinfected (*I* ~*k*~), Pre-AIDS (*P*), coinfected pre-AIDS (*P* ~*k*~), and those receiving HAART treatment (*T*). The partial reproductive number *ℛ* ~*T*~ representing the contribution of groups in receipt of ART is split into *ℛ* ~*T*~1~~, *ℛ* ~*T*~2~~, *ℛ* ~*T*~3~~, *ℛ* ~*T*~4~~, and *ℛ* ~*T*~5~~ and represents the contribution of HIV infectives, infectives dually infected with KS, Pre-AIDS infectives, and Pre-AIDS infectives dually infected with KS, respectively, who receive anti-retroviral therapy.

If we define *ℛ* ~0~ to be the basic HIV reproductive number in the absence of KS and HIV treatment and set parameters related to KS and treatment to zero in ([14](#EEq8){ref-type="disp-formula"}) we obtain $$\begin{matrix}
{\mathcal{R}_{K\, \mid \,\epsilon_{1} = \epsilon_{2} = \phi_{1} = \phi_{2} = 0} = \mathcal{R}_{0} = \mathcal{R}_{I} + \mathcal{R}_{P}.} \\
\end{matrix}$$

If we define the partial reproductive number without treatment to be *ℛ* ~*NT*~ and set parameters related to treatment to zero then we obtain $$\begin{matrix}
{\mathcal{R}_{K\, \mid \,\phi_{1} = \phi_{2} = 0} = \mathcal{R}_{NT},} \\
{= \mathcal{R}_{I} + \mathcal{R}_{I_{K}} + \mathcal{R}_{P} + \mathcal{R}_{P_{K}}} \\
{> \mathcal{R}_{0}.} \\
\end{matrix}$$

If *ℛ* ~0~ \> 1, then not providing treatment to all infective classes worsens the HIV in this population. Note that even if *ℛ* ~0~ \< 1, the option not to provide treatment to all infective classes could increase the reproduction number above 1. Treatment to all infective classes is necessary to effectively control the HIV disease spread. Using sensitivity analysis on *ℛ* ~*K*~, we have reinforced some of these findings as shown in [Figure 2](#fig2){ref-type="fig"}.

From Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"} wem note that an increase in the rate of infected people who develop KS will lead to an increase in *ℛ* ~*K*~ and consequently an increase in the HIV epidemic. However, an increase in the rate of progress to dual infection for people in the pre-AIDS class will result in a marginal increase of *ℛ* ~*K*~ and hence the HIV epidemic.

Figures [2(c)](#fig2){ref-type="fig"} and [2(d)](#fig2){ref-type="fig"} show that treatment of infected individuals and dually infected individuals will have a much higher positive impact on *ℛ* ~*K*~ and the epidemic than treatment at the pre-AIDS stage and this leads us to conclude that early administration of HAART on HIV infectives to curtail the growth of opportunistic infections, such as KS, will have a more positive impact than delayed therapy at the pre-AIDS stage.

4. Numerical Simulations {#sec4}
========================

Using the R programming environment, we ran numerical simulations of the model. The following data were input as initial conditions: $$\begin{matrix}
{N_{0} = \left\lbrack {I,I_{k},P,P_{k},T,A,A_{k},S} \right\rbrack = \left\lbrack {1,0,0,0,0,0,0,800} \right\rbrack.} \\
\end{matrix}$$

Parameter values used in the numerical simulations of model system ([2](#EEq2){ref-type="disp-formula"}) are shown in [Table 1](#tab1){ref-type="table"}. HIV/KS coinfection study is still in its infancy. A number of numeric values for the parameters shown in [Table 1](#tab1){ref-type="table"} are reasonable estimates. Some of the parameters were estimated by modifying baseline values from published literature and these are denoted with an asterisk in [Table 1](#tab1){ref-type="table"}.

Our value for the rate of HIV transmission is the average of the minimum (0.011) and maximum values (0.95) for the same parameter in Baggaley et al. \[[@B1]\] and Boily et al. \[[@B4]\]. We assumed that a death rate due to AIDS and KS coinfection would be 0.4; in our model, *δ* ~1~ and *δ* ~2~ are summed. Our recruitment rate is calculated by incorporating an annual recruitment rate (0.029) from Malunguza et al. \[[@B14]\]. In this study, we take the population of sub-Sahara Africa to be 767 million as in Mukandawire et al. \[[@B8]\] and Barley et al. \[[@B9]\].

[Figure 3(a)](#fig3){ref-type="fig"} shows that in the absence of treatment, the number of individuals with the AIDS/KS coinfection exceeds the number of those with just AIDS; that is, 54.0% of the total AIDS population has KS by the end of the model. Merely affecting a treatment rate of 1%, is enough to reverse this relation as depicted in [Figure 3(b)](#fig3){ref-type="fig"} where 61.7% of all AIDS patients are devoid of KS. If the treatment rate is increased to 10%, the AIDS population without the coinfection increases to 85.7% as depicted in [Figure 3(c)](#fig3){ref-type="fig"}. Using parameter values in [Table 1](#tab1){ref-type="table"} causes the model to tend towards some endemic equilibrium over time. In other words, the DFE is unstable, and so we expect *ℛ* ~0~ \> 1. In fact, carrying out these computations with *ϕ* ~1~ = *ϕ* ~2~ = 0.1, we obtain *ℛ* ~0~ ≈ 4.55. This value is slightly higher than estimated values of *ℛ* ~0~ for HIV/AIDS in European countries, which is consistent with our expectations \[[@B19]\].

[Figure 3(d)](#fig3){ref-type="fig"} provides an interesting insight into the predictions of our model. By providing treatment to 100% of all infectives and pre-AIDS individuals the model fails to eradicate the coinfection, and approximately an 8% prevalence of the coinfection among the full-blown AIDS cohort exists. This result means that we need to be cognisant of two objectives, namely, that we should have benchmark target goals in the provision of treatment and that work should be done to decrease the number of patients entering the pre-AIDS coinfection class. It is entirely unrealistic to presume that the coinfection can be eliminated entirely based on providing treatment to infectives and pre-AIDS individuals alone. In fact, [Figure 3(d)](#fig3){ref-type="fig"} shows that providing a treatment rate of *ϕ* ~1~ = *ϕ* ~2~ = 0.2 results in about 90% of the AIDS population losing the coinfection. Providing any further increases to *ϕ* ~1~ and *ϕ* ~2~ results in only a 2% increase.

Our model makes no attempt to consider the cost associated with providing the kind of treatment we have discussed. However, it is noteworthy to consider that the gains associated with providing treatment to any more than 20% of all infectives and pre-AIDS individuals are minimal. It is clear that there is an 8% gap between where we would like to see the percentage of the full-blown AIDS cohort without coinfection and where our model currently estimates that percentage to be. Assuming that it is unrealistic to completely eradicate the coinfection, steps should be taken to shift the curve in [Figure 3(d)](#fig3){ref-type="fig"} closer to 100%. We believe that a good way to do this is by screening patients for the coinfection once the HIV infection is first diagnosed. In general, this will serve to decrease the total number of patients who become pre-AIDS with the coinfection and, in turn, this will decrease the total number of individuals presenting with the coinfection.

5. Discussion {#sec5}
=============

In numerous HIV-positive cohorts, susceptibility to KS development is incredibly high. Recent findings that antiretroviral treatment for HIV clinical symptoms can reverse KS in most patients suggest that the only obstacle in preventing KS-related complications (or even deaths) is one\'s ability to access the treatment itself. This is especially the case in sub-Saharan Africa, where KS prevalence is higher than anywhere else in the world, yet access to proper treatment remains low. We have shown that providing treatment to just 10% of HIV-infected individuals, regardless of their KS status, can offer a significant reduction in the overall number of individuals who end up with full-blown AIDS and KS. Certainly, we expect that, as we increase the treatment rate, the disparity will become more and more favorable. However, our results only apply to situations in which individuals develop KS on their own---that is, in the absence of interaction with HHV-8-infected individuals. While such a generalization may be perfectly valid in sub-Saharan Africa, it will not apply to other regions where HHV-8 needs to be acquired sexually or through saliva. In other words, this model is very specific to the sub-Saharan region.

In the future, we hope to extend this model to consider all modes of HHV-8 transmission. One way to do this is by introducing separate classes of HHV-8 infectious individuals. This will increase the overall reach of the model and hopefully provide a positive influence on policy making in areas affected by KS. For now, supporting KS education and awareness needs to become as important as providing universal access to antiretroviral treatment for HIV patients. Most southern African countries already have programs in place to encourage HIV screening; this is the perfect time to also test for HHV-8 and provide KS counseling. Regardless of how long the HIV/AIDS epidemic lasts in Africa, there is no reason people should have to fight KS as well.

This work was done under SAMSA Masamu Program with support from the National Science Foundation under Grant no. DMS-1050259. Lungu acknowledges the support of the University of Botswana, Massaro would like to acknowledge partial support from the NSF SCALE-IT graduate fellowship program at the University of Tennessee, and Malunguza acknowledges the support of the National University of Science and Technology.

![Model flow diagram.](CMMM2013-753424.001){#fig1}

![(a) 3D plot of *ℛ* ~*K*~ against the rates of KS manifestation for infected and pre-AIDS classes for variable values of *ϵ* ~1~ and *ϵ* ~2~, all other parameters constant as in [Table 1](#tab1){ref-type="table"}, (b) contour plot map of *ℛ* ~*K*~ against *ϵ* ~1~ and *ϵ* ~2~, all other parameters constant as in [Table 1](#tab1){ref-type="table"}, (c) 3D plot of *ℛ* ~*K*~ against the rates of ART administration for infected and pre-AIDS classes for variable values of *ϕ* ~1~ and *ϕ* ~2~, all other parameters constant as in [Table 1](#tab1){ref-type="table"}, and (d) contour plot map of *ℛ* ~*K*~ against *ϕ* ~1~ and *ϕ* ~2~, all other parameters constant as in [Table 1](#tab1){ref-type="table"}.](CMMM2013-753424.002){#fig2}

![Epidemic curves for our model with the following treatment scenarios: (a) no treatment (*ϕ* ~1~ = *ϕ* ~2~ = 0), (b) 1% treatment level (*ϕ* ~1~ = *ϕ* ~2~ = 0.01), and (c) 10% treatment level (*ϕ* ~1~ = *ϕ* ~2~ = 0), (d) treatment rate versus AIDS population without coinfection. A treatment level of 10% is sufficient at minimizing endemic populations in all the infective, untreated classes at the equilibrium.](CMMM2013-753424.003){#fig3}

###### 

Parameter values and their estimates.

  Parameter                                                    Symbol    Value      Source
  ------------------------------------------------------------ --------- ---------- -----------------------------------------------
  HIV rate of transmission                                     *β*       0.4801\*   Baggaley et al. \[[@B1]\],
  Boily et al. \[[@B4]\]                                                            
  Death due to AIDS                                            *δ* ~1~   0.333      Malunguza et al. \[[@B14]\],
  Mukandavire et al. \[[@B15]\]                                                     
  Death due to AIDS with KS                                    *δ* ~2~   0.067\*    Malunguza et al. \[[@B14]\],
  Mukandavire et al. \[[@B15]\]                                                     
  Rate of KS acquisition among HIV-infected cohort             *ϵ* ~1~   0.001      Assumed
  Rate of KS acquisition among pre-AIDS cohort                 *ϵ* ~2~   0.002      Assumed
  Rate of KS acquisition among AIDS cohort                     *ϵ* ~3~   0.003      Assumed
  Relative HIV infectiousness of an HIV-infected individual    *γ* ~1~   0.8        Assumed
  Relative HIV infectiousness of a coinfected individual       *γ* ~2~   1.1        Assumed
  Relative HIV infectiousness of a pre-AIDS individual         *γ* ~3~   1.2        Assumed
  Relative HIV infectiousness of an AIDS individual            *γ* ~4~   1.3        Assumed
  Recruitment rate of sexually mature individuals              Λ         800\*      Barley et al. \[[@B2]\],
  Malunguza et al. \[[@B14]\]                                                       
  Mukandavire et al. \[[@B15], [@B16], [@B17]\]                                     
  Natural mortality rate                                       *μ*       0.02       Mukandavire et al. \[[@B15]\]
  Treatment rate of infected and coinfected cohorts            *ϕ* ~1~   Varies     Assumed
  Treatment rate of pre-AIDS and pre-AIDS coinfected cohorts   *ϕ* ~2~   Varies     Assumed
  Natural progression to pre-AIDS                              *ψ* ~1~   0.01       Assumed
  Rate of acute KS development in coinfected cohort            *τ* ~1~   0.0001     Assumed
  Rate of acute KS development in pre-AIDS coinfected cohort   *τ* ~2~   0.0002     Assumed
  Rate of acute KS development in AIDS coinfected cohort       *τ* ~3~   0.0003     Assumed
  Natural progression to AIDS                                  *θ* ~1~   0.1        Mukandavire et al. \[[@B15], [@B16], [@B17]\]
  Natural progression to AIDS after treatment                  *θ* ~2~   0.1        Assumed

\*Denotes a parameter obtained by modifying a value in the given source.

[^1]: Academic Editor: Gabriel Turinici
